Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection

Derseree Archary, Rong Rong, Michelle L. Gordon, Saikat Boliar, Maphuti Madiga, Elin S. Gray, Anne Sophie Dugast, Tandile Hermanus, Philip J.R. Goulder, Hoosen M. Coovadia, Lise Werner, Lynn Morris, Galit Alter, Cynthia A. Derdeyn, Thumbi Ndung'u*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically infected individuals with heterogeneous rates of disease progression. Autologous nAb titers of study exit plasma against study entry viruses were significantly higher than contemporaneous responses at study entry (p=0.002) and exit (p=0.01). NAb breadth and potencies against subtype C viruses were significantly higher than for subtype A (p=0.03 and p=0.01) or B viruses (p=0.03; p=0.05) respectively. Gp41-IgG binding affinity was higher than gp120-IgG (p=0.0002). IgG-FcγR1 affinity was significantly higher than FcγRIIIa (p<0.005) at study entry and FcγRIIb (p<0.05) or FcγRIIIa (p<0.005) at study exit. Evolving IgG binding suggests alteration of immune function mediated by binding antibodies. Evolution of nAbs was a potential marker of HIV-1 disease progression.

Original languageEnglish
Pages (from-to)410-420
Number of pages11
Issue number2
Publication statusPublished - 25 Nov 2012


  • Binding antibodies
  • Chronic infection
  • HIV-1 subtype C
  • Neutralizing antibodies

Cite this